<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030003129A1-20030102-D00001.TIF SYSTEM "US20030003129A1-20030102-D00001.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00002.TIF SYSTEM "US20030003129A1-20030102-D00002.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00003.TIF SYSTEM "US20030003129A1-20030102-D00003.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00004.TIF SYSTEM "US20030003129A1-20030102-D00004.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00005.TIF SYSTEM "US20030003129A1-20030102-D00005.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00006.TIF SYSTEM "US20030003129A1-20030102-D00006.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00007.TIF SYSTEM "US20030003129A1-20030102-D00007.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00008.TIF SYSTEM "US20030003129A1-20030102-D00008.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00009.TIF SYSTEM "US20030003129A1-20030102-D00009.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00010.TIF SYSTEM "US20030003129A1-20030102-D00010.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00011.TIF SYSTEM "US20030003129A1-20030102-D00011.TIF" NDATA TIF>
<!ENTITY US20030003129A1-20030102-D00012.TIF SYSTEM "US20030003129A1-20030102-D00012.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030003129</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>10187006</doc-number>
</application-number>
<application-number-series-code>10</application-number-series-code>
<filing-date>20020701</filing-date>
</domestic-filing-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>A61F002/00</ipc>
</classification-ipc-primary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>424</class>
<subclass>428000</subclass>
</uspc>
</classification-us-primary>
</classification-us>
<title-of-invention>Ophthalmic drug delivery device</title-of-invention>
</technical-information>
<continuity-data>
<continuations>
<continuation-of>
<parent-child>
<child>
<document-id>
<doc-number>10187006</doc-number>
<kind-code>A1</kind-code>
<document-date>20020701</document-date>
</document-id>
</child>
<parent>
<document-id>
<doc-number>09664790</doc-number>
<document-date>20000919</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>GRANTED</parent-status>
<parent-patent>
<document-id>
<doc-number>6416777</doc-number>
<country-code>US</country-code>
</document-id>
</parent-patent>
</parent-child>
</continuation-of>
</continuations>
<non-provisional-of-provisional>
<document-id>
<doc-number>60160673</doc-number>
<document-date>19991021</document-date>
<country-code>US</country-code>
</document-id>
</non-provisional-of-provisional>
</continuity-data>
<inventors>
<first-named-inventor>
<name>
<given-name>Yoseph</given-name>
<family-name>Yaacobi</family-name>
</name>
<residence>
<residence-us>
<city>Fort Worth</city>
<state>TX</state>
<country-code>US</country-code>
</residence-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
</inventors>
<correspondence-address>
<name-1>ALCON RESEARCH, LTD.</name-1>
<name-2></name-2>
<address>
<address-1>R&amp;D COUNSEL, Q-148</address-1>
<address-2>6201 SOUTH FREEWAY</address-2>
<city>FORT WORTH</city>
<state>TX</state>
<postalcode>76134-2099</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Methods of delivery a pharmaceutically active agent to the posterior segment of the human eye are also disclosed. </paragraph>
</subdoc-abstract>
<subdoc-description>
<cross-reference-to-related-applications>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> This application is a continuation of U.S. application Ser. No. 09/664,790, filed Sep. 19, 2000, now U.S. Pat. No. 6,416,777, which claims priority from U.S. Provisional Application No. 60/160,673, filed Oct. 21, 1999.</paragraph>
</cross-reference-to-related-applications>
<summary-of-invention>
<section>
<heading lvl="1">FIELD OF THE INVENTION </heading>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> The present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye. </paragraph>
</section>
<section>
<heading lvl="1">DESCRIPTION OF THE RELATED ART </heading>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Several diseases and conditions of the posterior segment of the eye threaten vision. Age related macular degeneration (ARMD), choroidal neovascularization (CNV), retinopathies (e.g., diabetic retinopathy, vitreoretinopathy), retinitis (e.g., cytomegalovirus (CMV) retinitis), uveitis, macular edema, glaucoma, and neuropathies are several examples. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> Age related macular degeneration (ARMD) is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and other detailed tasks difficult or impossible. About 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over age 75, and approximately twenty percent of the population over age 60, suffer from some degree of macular degeneration. &ldquo;Wet&rdquo; ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive damage to the retina. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> In the particular case of CNV in ARMD, three main methods of treatment are currently being developed, (a) photocoagulation, (b) the use of angiogenesis inhibitors, and (c) photodynamic therapy. Photocoagulation is the most common treatment modality for CNV. However, photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea. Furthermore, over time, photocoagulation often results in recurrent CNV. Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD. However, due to drug-specific metabolic restrictions, systemic administration usually provides sub-therapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required. Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis. Photodynamic therapy is a new technology for which the long-term efficacy is still largely unknown. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> In order to prevent complications related to the above-described treatments and to provide better ocular treatment, researchers have suggested various implants aimed at localizing delivery of anti-angiogenic compounds to the eye. U.S. Pat. No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein. The pharmaceutically active agent diffuses through the polymer body of the implant into the target tissue. The pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy. The implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or intrasclerally over an avascular region; substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in direct communication with the vitreous. </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> U.S. Pat. No. 5,476,511 to Gwon et al. discloses a polymer implant for placement under the conjunctiva of the eye. The implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, and retinitis. The pharmaceutically active agent diffuses through the polymer body of the implant. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> U.S. Pat. No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as cyclosporine for the treatment of uveitis. Once again, the pharmaceutically active agent diffuses through the polymer body of the implant. </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> All of the above-described implants require careful design and manufacture to permit controlled diffusion of the pharmaceutically active agent through a polymer body (i.e., matrix devices) or polymer membrane (i.e., reservoir devices) to the desired site of therapy. Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> U.S. Pat. No. 5,824,073 to Peyman discloses an indentor for positioning in the eye. The indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye. This patent discloses that such pressure decreases choroidal congestion and blood flow through the subretinal neovascular membrane, which, in turn, decreases bleeding and subretinal fluid accumulation. </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> Therefore, a need exists in the biocompatible implant field for a surgically implantable ophthalmic drug delivery device capable of safe, effective, rate-controlled, localized delivery of a wide variety of pharmaceutically active agents. The surgical procedure for implanting such a device should be safe, simple, quick, and capable of being performed in an outpatient setting. Ideally, such a device should be easy and economical to manufacture. Furthermore, because of its versatility and capability to deliver a wide variety of pharmaceutically active agents, such an implant should be capable of use in ophthalmic clinical studies to deliver various agents that create a specific physical condition in a patient. Such an ophthalmic drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. </paragraph>
</section>
<section>
<heading lvl="1">SUMMARY OF THE INVENTION </heading>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Because of its unique geometry, the device is especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. </paragraph>
</section>
</summary-of-invention>
<brief-description-of-drawings>
<section>
<heading lvl="1">BRIEF DESCRIPTION OF THE DRAWINGS </heading>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> For a more complete understanding of the present invention, and for further objects and advantages thereof, reference is made to the following description taken in conjunction with the accompanying drawings in which: </paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 1</cross-reference> is a side sectional view schematically illustrating the human eye and an ophthalmic drug delivery device implanted in the posterior segment of the eye according to the present invention; </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 2</cross-reference> is detailed cross-sectional view of the eye of <cross-reference target="DRAWINGS">FIG. 1</cross-reference> along line <highlight><bold>2</bold></highlight>-<highlight><bold>2</bold></highlight>; </paragraph>
<paragraph id="P-0016" lvl="0"><number>&lsqb;0016&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 3</cross-reference> is a three dimensional schematic representation of the human eye in situ; </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 4</cross-reference> shows the eye of <cross-reference target="DRAWINGS">FIG. 3</cross-reference> after partial removal of the lateral rectus muscle; </paragraph>
<paragraph id="P-0018" lvl="0"><number>&lsqb;0018&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 5</cross-reference> is a schematic representation of the anterior view of a human eye; </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 6</cross-reference> is a schematic representation of the posterior view of a human eye; </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 7</cross-reference> is a perspective, orbital view of an ophthalmic drug delivery device for the right human eye according to a first preferred embodiment of the present invention; </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 8</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference> including a ramp for mating with the inferior oblique muscle; </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 9</cross-reference> is a perspective, scleral view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIG. 7</cross-reference>; </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 10</cross-reference> is a perspective view of an oval shaped drug core or tablet for use with the ophthalmic drug delivery devices of the present invention; </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 11</cross-reference> is a perspective view of two, mating half-oval shaped drug cores or tablets for use with the ophthalmic drug delivery devices of the present invention; </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 12</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference> for the left human eye; </paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 13</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIGS. 12 and 14</cross-reference> including a ramp for mating with the inferior oblique muscle; </paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 14</cross-reference> is a perspective, scleral view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference> for the left human eye; </paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 15</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference> including a tapered longitudinal part of the device; </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 16</cross-reference> is a perspective, orbital view of a shortened version of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>; </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 17</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIG. 16</cross-reference> including a ramp for mating with the inferior oblique muscle; </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 18</cross-reference> is a perspective, orbital view of an ophthalmic drug delivery device for the right human eye according to a second preferred embodiment of the present invention; </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 19</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIG. 18</cross-reference> including a ramp for mating with the inferior oblique muscle; </paragraph>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 20</cross-reference> is a perspective, orbital view of an ophthalmic drug delivery device for the right human eye according to a third preferred embodiment of the present invention; and </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 21</cross-reference> is a perspective, orbital view of the ophthalmic drug delivery device of <cross-reference target="DRAWINGS">FIG. 20</cross-reference> including a ramp for mating with the inferior oblique muscle.</paragraph>
</section>
</brief-description-of-drawings>
<detailed-description>
<section>
<heading lvl="1">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS </heading>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> The preferred embodiments of the present invention and their advantages are best understood by referring to <cross-reference target="DRAWINGS">FIGS. 1 through 21</cross-reference> of the drawings, like numerals being used for like and corresponding parts of the various drawings. </paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> <cross-reference target="DRAWINGS">FIGS. 1 through 6</cross-reference> illustrate various portions of the human eye important to a complete understanding of the present invention. Referring first to <cross-reference target="DRAWINGS">FIG. 1, a</cross-reference> human eye <highlight><bold>90</bold></highlight> is schematically illustrated. Eye <highlight><bold>90</bold></highlight> has a cornea <highlight><bold>92</bold></highlight>, a lens <highlight><bold>93</bold></highlight>, vitreous <highlight><bold>95</bold></highlight>, a sclera <highlight><bold>100</bold></highlight>, a choroid <highlight><bold>99</bold></highlight>, a retina <highlight><bold>97</bold></highlight>, and an optic nerve <highlight><bold>96</bold></highlight>. Eye <highlight><bold>90</bold></highlight> is generally divided into an anterior segment <highlight><bold>89</bold></highlight> and a posterior segment <highlight><bold>88</bold></highlight>. Anterior segment <highlight><bold>89</bold></highlight> of eye <highlight><bold>90</bold></highlight> generally includes the portions of eye <highlight><bold>90</bold></highlight> anterior of ora serata <highlight><bold>11</bold></highlight>. Posterior segment <highlight><bold>88</bold></highlight> of eye <highlight><bold>90</bold></highlight> generally includes the portions of eye <highlight><bold>90</bold></highlight> posterior of ora serata <highlight><bold>11</bold></highlight>. Retina <highlight><bold>97</bold></highlight> is physically attached to choroid <highlight><bold>99</bold></highlight> in a circumferential manner proximate pars plana <highlight><bold>13</bold></highlight>, posteriorly to optic disk <highlight><bold>19</bold></highlight>. Retina <highlight><bold>97</bold></highlight> has a macula <highlight><bold>98</bold></highlight> located slightly lateral to optic disk <highlight><bold>19</bold></highlight>. As is well known in the ophthalmic art, macula <highlight><bold>98</bold></highlight> is comprised primarily of retinal cones and is the region of maximum visual acuity in retina <highlight><bold>97</bold></highlight>. A Tenon&apos;s capsule or Tenon&apos;s membrane <highlight><bold>101</bold></highlight> is disposed on sclera <highlight><bold>100</bold></highlight>. A conjunctiva <highlight><bold>94</bold></highlight> covers a short area of the globe of eye <highlight><bold>90</bold></highlight> posterior to limbus <highlight><bold>115</bold></highlight> (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas of upper eyelid <highlight><bold>78</bold></highlight> and lower eyelid <highlight><bold>79</bold></highlight>, respectively. Conjunctiva <highlight><bold>94</bold></highlight> is disposed on top of Tenon&apos;s capsule <highlight><bold>101</bold></highlight>. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> As is shown in <cross-reference target="DRAWINGS">FIGS. 1 and 2</cross-reference>, and as is described in greater detail hereinbelow, device <highlight><bold>50</bold></highlight> is preferably disposed directly on the outer surface of sclera <highlight><bold>100</bold></highlight>, below Tenon&apos;s capsule <highlight><bold>101</bold></highlight> for treatment of most posterior segment diseases or conditions. In addition, for treatment of ARMD and CNV in humans, device <highlight><bold>50</bold></highlight> is preferably disposed directly on the outer surface of sclera <highlight><bold>100</bold></highlight>, below Tenon&apos;s capsule <highlight><bold>101</bold></highlight>, with an inner core of device <highlight><bold>50</bold></highlight> proximate macula <highlight><bold>98</bold></highlight>. </paragraph>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 3</cross-reference> illustrates a left human eye <highlight><bold>90</bold></highlight> within its orbit <highlight><bold>112</bold></highlight>. As can be seen from <cross-reference target="DRAWINGS">FIG. 3</cross-reference>, inferior oblique muscle <highlight><bold>107</bold></highlight> runs under lateral rectus muscle <highlight><bold>105</bold></highlight>. The insertion line <highlight><bold>107</bold></highlight><highlight><italic>a </italic></highlight>of inferior oblique muscle <highlight><bold>107</bold></highlight> into sclera <highlight><bold>100</bold></highlight> is located just above the superior border of lateral rectus muscle <highlight><bold>105</bold></highlight>. Of course, the position of the inferior oblique muscle in a right human eye <highlight><bold>90</bold></highlight> is a mirror image to its position on left human eye <highlight><bold>90</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 3</cross-reference>. Cornea <highlight><bold>92</bold></highlight>, conjunctiva <highlight><bold>94</bold></highlight>, superior rectus muscle <highlight><bold>103</bold></highlight>, inferior rectus muscle <highlight><bold>104</bold></highlight>, superior oblique muscle <highlight><bold>106</bold></highlight>, and limbus <highlight><bold>115</bold></highlight> are also shown in <cross-reference target="DRAWINGS">FIG. 3</cross-reference>. </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 4</cross-reference> similarly shows a left human eye <highlight><bold>90</bold></highlight> within its orbit <highlight><bold>112</bold></highlight>. However, a portion of lateral rectus muscle <highlight><bold>105</bold></highlight> is not shown in <cross-reference target="DRAWINGS">FIG. 4</cross-reference> to allow visibility of the portion of sclera <highlight><bold>100</bold></highlight> and optic nerve <highlight><bold>96</bold></highlight> usually hidden by the muscle. In <cross-reference target="DRAWINGS">FIG. 4</cross-reference>, an insertion line <highlight><bold>107</bold></highlight><highlight><italic>b </italic></highlight>of inferior oblique muscle <highlight><bold>107</bold></highlight> into sclera <highlight><bold>100</bold></highlight> is lower than insertion line <highlight><bold>107</bold></highlight><highlight><italic>a </italic></highlight>of <cross-reference target="DRAWINGS">FIG. 3</cross-reference>, indicating the representative physiological variability of the insertion line of the inferior oblique muscle in the human eye. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 5</cross-reference> schematically illustrates an anterior view of human eye <highlight><bold>90</bold></highlight> with its four recti muscles, the superior rectus muscle <highlight><bold>103</bold></highlight>, the medial rectus muscle <highlight><bold>108</bold></highlight>, the inferior rectus muscle <highlight><bold>104</bold></highlight>, and the lateral rectus muscle <highlight><bold>105</bold></highlight>. <cross-reference target="DRAWINGS">FIG. 5</cross-reference> also shows the relationship between the limbus, represented in <cross-reference target="DRAWINGS">FIG. 5</cross-reference> by circumferential line <highlight><bold>115</bold></highlight>, and the insertion lines of the recti muscles, represented in <cross-reference target="DRAWINGS">FIG. 5</cross-reference> by circumferential lines <highlight><bold>113</bold></highlight>. </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> The posterior view of human eye <highlight><bold>90</bold></highlight> is schematically illustrated in <cross-reference target="DRAWINGS">FIG. 6</cross-reference>. <cross-reference target="DRAWINGS">FIG. 6</cross-reference> shows the locations of the superior rectus muscle <highlight><bold>103</bold></highlight>, the lateral rectus muscle <highlight><bold>105</bold></highlight>, the inferior rectus muscle <highlight><bold>104</bold></highlight>, the medial rectus muscle <highlight><bold>108</bold></highlight>, the superior oblique muscle <highlight><bold>106</bold></highlight>, the inferior oblique muscle <highlight><bold>107</bold></highlight> and its insertion line <highlight><bold>107</bold></highlight><highlight><italic>a</italic></highlight>, the optic nerve <highlight><bold>96</bold></highlight>, the cilliary vessels <highlight><bold>109</bold></highlight>, the sclera <highlight><bold>100</bold></highlight>, the scleral area <highlight><bold>110</bold></highlight> above macula <highlight><bold>98</bold></highlight>, the long cilliary arteries <highlight><bold>111</bold></highlight>, and the vortex veins <highlight><bold>114</bold></highlight>. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference> schematically illustrate an ophthalmic drug delivery device <highlight><bold>50</bold></highlight> for the right human eye according to a first preferred embodiment of the present invention. Device <highlight><bold>50</bold></highlight> may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required. Device <highlight><bold>50</bold></highlight> is particularly useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye. A preferred use for device <highlight><bold>50</bold></highlight> is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. </paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number> Device <highlight><bold>50</bold></highlight> generally includes a body <highlight><bold>21</bold></highlight> having a convex, dome-shaped, orbital surface <highlight><bold>12</bold></highlight> and a concave, dome-shaped, scleral surface <highlight><bold>14</bold></highlight>. Scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature that facilitates direct contact with sclera <highlight><bold>100</bold></highlight>. Most preferably, scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature equal to the radius of curvature <highlight><bold>91</bold></highlight> of an average human eye <highlight><bold>90</bold></highlight>. (See <cross-reference target="DRAWINGS">FIG. 1</cross-reference>) Orbital surface <highlight><bold>12</bold></highlight> is preferably designed with a radius of curvature that facilitates implantation under Tenon&apos;s capsule <highlight><bold>101</bold></highlight>. When viewed from the top, body <highlight><bold>21</bold></highlight> preferably has a generally &ldquo;F-shaped&rdquo; geometry with a longitudinal part <highlight><bold>15</bold></highlight>, a transversal part <highlight><bold>18</bold></highlight>, and a knee <highlight><bold>32</bold></highlight> therebetween. Longitudinal part <highlight><bold>15</bold></highlight> and transversal part <highlight><bold>18</bold></highlight> are preferably joined at knee <highlight><bold>32</bold></highlight> to form an angle of about ninety degrees. Longitudinal part <highlight><bold>15</bold></highlight> has a proximal end <highlight><bold>25</bold></highlight>, a rounded edge <highlight><bold>24</bold></highlight>, a stopper <highlight><bold>36</bold></highlight>, and a notch <highlight><bold>42</bold></highlight>. As is described in more detail hereinbelow, notch <highlight><bold>42</bold></highlight> is designed to accommodate the origin of inferior oblique muscle <highlight><bold>107</bold></highlight>. Stopper <highlight><bold>36</bold></highlight> defines the lower portion of notch <highlight><bold>42</bold></highlight> and is preferably slightly elevated from the remainder of the generally convex orbital surface <highlight><bold>12</bold></highlight>. As is described in greater detail hereinbelow, stopper <highlight><bold>36</bold></highlight> is designed to prevent excessive advancement of device <highlight><bold>50</bold></highlight> toward optic nerve <highlight><bold>96</bold></highlight> through contact on the anterior border of inferior oblique muscle <highlight><bold>107</bold></highlight>. Transversal part <highlight><bold>18</bold></highlight> has a distal end <highlight><bold>58</bold></highlight>, a rounded edge <highlight><bold>28</bold></highlight>, and a well or cavity <highlight><bold>20</bold></highlight> having an opening <highlight><bold>64</bold></highlight> to scleral surface <highlight><bold>14</bold></highlight>. Well <highlight><bold>20</bold></highlight> and opening <highlight><bold>64</bold></highlight> preferably have a generally oval shape. As is explained in more detail hereinbelow, transversal part <highlight><bold>18</bold></highlight> allows cavity <highlight><bold>20</bold></highlight> to be placed more directly over the area of sclera <highlight><bold>100</bold></highlight> overlying macula <highlight><bold>98</bold></highlight>. </paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> An inner core <highlight><bold>81</bold></highlight>, which is shown in <cross-reference target="DRAWINGS">FIG. 10</cross-reference>, is preferably disposed in well <highlight><bold>20</bold></highlight>. As shown in <cross-reference target="DRAWINGS">FIG. 10</cross-reference>, inner core <highlight><bold>81</bold></highlight> is preferably a tablet comprising one or more pharmaceutically active agents. Tablet <highlight><bold>81</bold></highlight> preferably has a generally oval body <highlight><bold>46</bold></highlight> with a concave, dome-shaped, scleral surface <highlight><bold>85</bold></highlight> and a convex, dome-shaped, orbital surface <highlight><bold>86</bold></highlight>. Body <highlight><bold>46</bold></highlight> also preferably has a peripheral bevel <highlight><bold>87</bold></highlight> disposed thereon. Alternatively, as shown in <cross-reference target="DRAWINGS">FIG. 11</cross-reference>, the inner core may comprise mating, half-oval tablets <highlight><bold>82</bold></highlight><highlight><italic>a </italic></highlight>and <highlight><bold>82</bold></highlight><highlight><italic>b</italic></highlight>. Tablet <highlight><bold>82</bold></highlight><highlight><italic>a </italic></highlight>preferably has a body <highlight><bold>47</bold></highlight> identical to one half of body <highlight><bold>46</bold></highlight> of tablet <highlight><bold>81</bold></highlight>. Tablet <highlight><bold>82</bold></highlight><highlight><italic>b </italic></highlight>preferably has a body <highlight><bold>48</bold></highlight> equal to the opposite half of body <highlight><bold>46</bold></highlight> of tablet <highlight><bold>81</bold></highlight>. Still further in the alternative, inner core <highlight><bold>81</bold></highlight>, or inner cores <highlight><bold>82</bold></highlight><highlight><italic>a </italic></highlight>and <highlight><bold>82</bold></highlight><highlight><italic>b</italic></highlight>, may comprise a conventional hydrogel, gel, paste, or other semi-solid dosage form having one or more pharmaceutically active agents disposed therein. </paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> Returning to <cross-reference target="DRAWINGS">FIG. 9, a</cross-reference> retaining member <highlight><bold>62</bold></highlight> is preferably disposed proximate opening <highlight><bold>64</bold></highlight>. Retaining member <highlight><bold>62</bold></highlight> prevents inner core <highlight><bold>81</bold></highlight> from falling out of well <highlight><bold>20</bold></highlight>. When inner core <highlight><bold>81</bold></highlight> is a tablet, retaining member <highlight><bold>62</bold></highlight> is preferably a continuous rim or lip disposed circumferentially around opening <highlight><bold>64</bold></highlight> that is designed to accommodate bevel <highlight><bold>87</bold></highlight> of tablet <highlight><bold>81</bold></highlight>. Alternatively, retaining member <highlight><bold>62</bold></highlight> may comprise one or more members that extend from body <highlight><bold>21</bold></highlight> into opening <highlight><bold>64</bold></highlight>. </paragraph>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number> Although not shown in <cross-reference target="DRAWINGS">FIGS. 9 through 11</cross-reference>, inner core <highlight><bold>81</bold></highlight> may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents. In this embodiment, scleral surface <highlight><bold>14</bold></highlight> is formed without opening <highlight><bold>64</bold></highlight>, and the suspension, solution, powder, or combination thereof diffuses through a relatively thin extension of scleral surface <highlight><bold>14</bold></highlight> or other membrane below inner core <highlight><bold>81</bold></highlight>. Still further in the alternative, device <highlight><bold>50</bold></highlight> may be formed without well <highlight><bold>20</bold></highlight> or inner core <highlight><bold>81</bold></highlight>, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body <highlight><bold>21</bold></highlight> of device <highlight><bold>50</bold></highlight>. In this embodiment, the pharmaceutically active agent diffuses through body <highlight><bold>21</bold></highlight> into the target tissue. </paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> The geometry and dimensions of device <highlight><bold>50</bold></highlight> maximize communication between the pharmaceutically active agent of inner core <highlight><bold>81</bold></highlight> and the tissue underlying scleral surface <highlight><bold>14</bold></highlight>. Scleral surface <highlight><bold>14</bold></highlight> preferably physically contacts the outer surface of sclera <highlight><bold>100</bold></highlight>. Alternatively, scleral surface <highlight><bold>14</bold></highlight> may be disposed proximate the outer surface of sclera <highlight><bold>100</bold></highlight>. By way of example, device <highlight><bold>50</bold></highlight> may be disposed in the periocular tissues just above the outer surface of sclera <highlight><bold>100</bold></highlight> or intra-lamellarly within sclera <highlight><bold>100</bold></highlight>. </paragraph>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> Body <highlight><bold>21</bold></highlight> preferably comprises a biocompatible, non-bioerodable material. Body <highlight><bold>21</bold></highlight> more preferably comprises a biocompatible, non-bioerodable polymeric composition. Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend. Examples of polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof. Examples of suitable soft acrylics are more fully disclosed in U.S. Pat. No. 5,403,901, which is incorporated herein in its entirety by reference. Said polymeric composition most preferably comprises silicone. Of course, said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants. Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body <highlight><bold>21</bold></highlight>&mdash;inner core <highlight><bold>81</bold></highlight> interaction. Body <highlight><bold>21</bold></highlight> is preferably impermeable to the pharmaceutically active agent of inner core <highlight><bold>81</bold></highlight>. When body <highlight><bold>21</bold></highlight> is made from a generally elastic polymeric composition, the shape of well <highlight><bold>20</bold></highlight> may be made slightly smaller than the shape of inner core <highlight><bold>81</bold></highlight>. This frictional fit secures inner core <highlight><bold>81</bold></highlight> within well <highlight><bold>20</bold></highlight>. In this embodiment, body <highlight><bold>21</bold></highlight> may be formed with or without retaining member <highlight><bold>62</bold></highlight>, and inner core <highlight><bold>81</bold></highlight> may be formed with or without bevel <highlight><bold>87</bold></highlight>, if desired. </paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number> Inner core <highlight><bold>81</bold></highlight> may comprise any ophthalmically acceptable pharmaceutically active agents suitable for localized delivery. Examples of pharmaceutically active agents suitable for inner core <highlight><bold>81</bold></highlight> are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenics and mast cell stabilizers; steroidal and nonsteroidal anti-inflammatory agents; cyclooxygenase inhibitors, including, without limitation, Cox I and Cox II inhibitors; combinations of anti-infective and antiinflammatory agents; anti-glaucoma agents, including, without limitation, adrenergics, &bgr;-adrenergic blocking agents, &agr;-adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections and CMV ocular infections; drugs for the treatment of proliferative vitreoretinopathy including, without limitation, antimetabolites and fibrinolytics; wound modulating agents, including, without limitation, growth factors; antimetabolites; neuroprotective drugs, including, without limitation, eliprodil; and angiostatic steroids for the treatment of diseases or conditions of the posterior segment of the eye, including, without limitation, ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma. Such angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference. Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17&agr;,21-diol-3,20-dione and 4,9(11)-Pregnadien-17&agr;,21-diol-3,20-dione-21-acetate. A preferred non-steroidal antiinflammatory for the treatment of cystoid macular edema is nepafenac. Inner core <highlight><bold>81</bold></highlight> may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core. </paragraph>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number> If inner core <highlight><bold>81</bold></highlight> is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods. The pharmaceutically active agent is preferably distributed evenly throughout the tablet. In addition to conventional tablets, inner core <highlight><bold>81</bold></highlight> may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. If inner core <highlight><bold>81</bold></highlight> is a hydrogel or other gel, such gels may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, such gels may be non-bioerodable but allow diffusion of the pharmaceutically active agent. </paragraph>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> Device <highlight><bold>50</bold></highlight> may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device <highlight><bold>50</bold></highlight> is formed using conventional injection molding techniques. Inner core <highlight><bold>81</bold></highlight> is preferably disposed in well <highlight><bold>20</bold></highlight> after the formation of body <highlight><bold>21</bold></highlight> of device <highlight><bold>50</bold></highlight>. Retaining member <highlight><bold>62</bold></highlight> is preferably resilient enough to allow bevel <highlight><bold>87</bold></highlight> of inner core <highlight><bold>81</bold></highlight> to be inserted through opening <highlight><bold>64</bold></highlight> and then to return to its original position. </paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> Device <highlight><bold>50</bold></highlight> is preferably surgically placed directly on the outer surface of sclera <highlight><bold>100</bold></highlight> below Tenon&apos;s capsule <highlight><bold>101</bold></highlight> with well <highlight><bold>20</bold></highlight> and inner core <highlight><bold>81</bold></highlight> directly over the area of sclera <highlight><bold>100</bold></highlight> above macula <highlight><bold>98</bold></highlight> using the following preferred technique that is capable of being performed in an outpatient setting. The surgeon first performs an 8 mm peritomy in one of the quadrants of eye <highlight><bold>90</bold></highlight>. Preferably, the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus <highlight><bold>115</bold></highlight> of eye <highlight><bold>90</bold></highlight>. Once this incision is made, the surgeon performs a blunt dissection to separate Tenon&apos;s capsule <highlight><bold>101</bold></highlight> from sclera <highlight><bold>100</bold></highlight>. Using scissors and blunt dissection, an antero-posterior tunnel is formed along the outer surface of sclera <highlight><bold>100</bold></highlight> and below inferior oblique muscle <highlight><bold>107</bold></highlight>, preferably following the inferior border of lateral rectus muscle <highlight><bold>105</bold></highlight>. The inferior oblique muscle <highlight><bold>107</bold></highlight> is then engaged with a Jamison muscle hook. The tip of the hook is then advanced just posterior to the inferior oblique muscle to form a portion of the tunnel that will accommodate transversal part <highlight><bold>18</bold></highlight> of device <highlight><bold>50</bold></highlight>. Once the tunnel is formed, the surgeon uses Nuggett forceps to hold transversal part <highlight><bold>18</bold></highlight> of device <highlight><bold>50</bold></highlight> with scleral surface <highlight><bold>14</bold></highlight> facing sclera <highlight><bold>100</bold></highlight> and distal end <highlight><bold>58</bold></highlight> of transversal part <highlight><bold>18</bold></highlight> away from the surgeon. The surgeon then introduces device <highlight><bold>50</bold></highlight>, distal end <highlight><bold>58</bold></highlight> first, into the tunnel at the level of the peritomy. Once in the tunnel, the surgeon advances device <highlight><bold>50</bold></highlight> along the tunnel toward inferior oblique muscle <highlight><bold>107</bold></highlight> until stopper <highlight><bold>36</bold></highlight> contacts the anterior border of muscle <highlight><bold>107</bold></highlight>. At the level of the visualized inferior oblique muscle <highlight><bold>107</bold></highlight>, the surgeon rotates device <highlight><bold>50</bold></highlight> underneath muscle <highlight><bold>107</bold></highlight> so that transversal portion <highlight><bold>18</bold></highlight> of device <highlight><bold>50</bold></highlight> enters the portion of the tunnel just posterior to inferior oblique muscle <highlight><bold>107</bold></highlight>. When the surgeon feels that knee <highlight><bold>32</bold></highlight> cannot advance any further, the surgeon slightly moves device <highlight><bold>50</bold></highlight> in an antero-posterior direction to allow for the accommodation of inferior oblique muscle <highlight><bold>107</bold></highlight> within notch <highlight><bold>42</bold></highlight> between transversal part <highlight><bold>18</bold></highlight> and stopper <highlight><bold>36</bold></highlight>. Due to the notch <highlight><bold>42</bold></highlight> and the location of well <highlight><bold>20</bold></highlight> near distal end <highlight><bold>58</bold></highlight> of transversal part <highlight><bold>18</bold></highlight>, inner core <highlight><bold>81</bold></highlight> is positioned directly over the portion of sclera <highlight><bold>100</bold></highlight> above macula <highlight><bold>98</bold></highlight>. Proximal end <highlight><bold>25</bold></highlight> of longitudinal part <highlight><bold>15</bold></highlight> may then be sutured to sclera <highlight><bold>100</bold></highlight>. The surgeon then closes the peritomy by suturing Tenon&apos;s capsule <highlight><bold>101</bold></highlight> and conjunctiva <highlight><bold>94</bold></highlight> to sclera <highlight><bold>100</bold></highlight>. After closing, the surgeon places a strip of antibiotic ointment on the surgical wound. All sutures are preferably 7-0 Vicryl sutures. For the treatment of ARMD and CNV, the pharmaceutically active agent of inner core <highlight><bold>81</bold></highlight> is preferably one of the angiostatic steroids disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592. </paragraph>
<paragraph id="P-0053" lvl="0"><number>&lsqb;0053&rsqb;</number> The geometry of body <highlight><bold>21</bold></highlight> of device <highlight><bold>50</bold></highlight>, including the concave nature of scleral surface <highlight><bold>14</bold></highlight>; the shape and locations of transversal portion <highlight><bold>18</bold></highlight>, well <highlight><bold>20</bold></highlight>, opening <highlight><bold>64</bold></highlight>, inner core <highlight><bold>81</bold></highlight>, and retaining member <highlight><bold>62</bold></highlight>; and the shape and locations of notch <highlight><bold>42</bold></highlight> and stopper <highlight><bold>36</bold></highlight>, all facilitate the delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core <highlight><bold>81</bold></highlight> through sclera <highlight><bold>100</bold></highlight>, choroid <highlight><bold>99</bold></highlight>, and into retina <highlight><bold>97</bold></highlight>, and more particularly into macula <highlight><bold>98</bold></highlight>. The absence of a polymer layer or membrane between inner core <highlight><bold>20</bold></highlight> and sclera <highlight><bold>100</bold></highlight> also greatly enhances and simplifies the delivery of an active agent to retina <highlight><bold>97</bold></highlight>. </paragraph>
<paragraph id="P-0054" lvl="0"><number>&lsqb;0054&rsqb;</number> It is believed that device <highlight><bold>50</bold></highlight> can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to retina <highlight><bold>97</bold></highlight> for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, partitioning coefficient, and tissue affinity. After inner core <highlight><bold>20</bold></highlight> no longer contains active agent, the surgeon may easily remove device <highlight><bold>50</bold></highlight>. In addition, the &ldquo;pre-formed&rdquo; tunnel facilitates the replacement of an old device <highlight><bold>50</bold></highlight> with a new device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0055" lvl="0"><number>&lsqb;0055&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 8</cross-reference> illustrates an ophthalmic drug delivery device <highlight><bold>60</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>50</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 8</cross-reference>, device <highlight><bold>60</bold></highlight> has a geometry substantially similar to device <highlight><bold>50</bold></highlight> of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>, with the exception that a ramp <highlight><bold>45</bold></highlight> has been added to orbital surface <highlight><bold>12</bold></highlight> of body <highlight><bold>21</bold></highlight> proximate notch <highlight><bold>42</bold></highlight>. Ramp <highlight><bold>45</bold></highlight> is a slanted surface that preferably travels from scleral surface <highlight><bold>14</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Alternatively, ramp <highlight><bold>45</bold></highlight> may travel from a location within edge <highlight><bold>24</bold></highlight> of longitudinal part <highlight><bold>15</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Ramp <highlight><bold>45</bold></highlight> facilitates the accommodation of inferior oblique muscle <highlight><bold>107</bold></highlight> within notch <highlight><bold>42</bold></highlight> between transversal part <highlight><bold>18</bold></highlight> and stopper <highlight><bold>36</bold></highlight> when device <highlight><bold>60</bold></highlight> is implanted within eye <highlight><bold>90</bold></highlight>, as described hereinabove in connection with device <highlight><bold>50</bold></highlight>. Device <highlight><bold>60</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0056" lvl="0"><number>&lsqb;0056&rsqb;</number> <cross-reference target="DRAWINGS">FIGS. 12 and 14</cross-reference> schematically illustrates an ophthalmic drug delivery device <highlight><bold>70</bold></highlight> for the left human eye. The geometry of device <highlight><bold>70</bold></highlight> is a mirror image of the geometry of device <highlight><bold>50</bold></highlight> for the right human eye as described hereinabove in connection with <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>. The use of device <highlight><bold>70</bold></highlight> is substantially identical to the use of device <highlight><bold>50</bold></highlight>, and device <highlight><bold>70</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0057" lvl="0"><number>&lsqb;0057&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 13</cross-reference> illustrates an ophthalmic drug delivery device <highlight><bold>75</bold></highlight> for the left human eye, a slight modification of ophthalmic drug delivery device <highlight><bold>70</bold></highlight> that is useful for certain implantations of the present invention. The geometry and use of device <highlight><bold>75</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 13</cross-reference> is substantially similar to the geometry and use of device <highlight><bold>60</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 8</cross-reference>, except that device <highlight><bold>75</bold></highlight> is a mirror image of device <highlight><bold>60</bold></highlight>. </paragraph>
<paragraph id="P-0058" lvl="0"><number>&lsqb;0058&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 15</cross-reference> schematically illustrates an ophthalmic drug delivery device <highlight><bold>30</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>50</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 15</cross-reference>, device <highlight><bold>30</bold></highlight> has a geometry substantially similar to device <highlight><bold>50</bold></highlight> of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>, with the exception that longitudinal part <highlight><bold>15</bold></highlight> has a tapered thickness, when viewed from edge <highlight><bold>24</bold></highlight>, preferably beginning at a location <highlight><bold>33</bold></highlight> and continuing to proximal end <highlight><bold>25</bold></highlight>. This portion of longitudinal part <highlight><bold>15</bold></highlight> is disposed anteriorly within eye <highlight><bold>90</bold></highlight> and may be visible to others. Therefore, due to this tapered thickness, device <highlight><bold>30</bold></highlight> may be more comfortable or cosmetically acceptable to the patient. The use of device <highlight><bold>30</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 15</cross-reference> is substantially similar to the use of device <highlight><bold>50</bold></highlight>, and device <highlight><bold>30</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0059" lvl="0"><number>&lsqb;0059&rsqb;</number> FIGS. <highlight><bold>16</bold></highlight> schematically illustrates an ophthalmic drug delivery device <highlight><bold>40</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>50</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 16</cross-reference>, device <highlight><bold>40</bold></highlight> has a geometry substantially similar to device <highlight><bold>50</bold></highlight> of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>, with the exception that a length of longitudinal part <highlight><bold>15</bold></highlight> in device <highlight><bold>40</bold></highlight> has been shortened relative to device <highlight><bold>50</bold></highlight>. Similar to device <highlight><bold>30</bold></highlight>, this shortening of longitudinal part <highlight><bold>15</bold></highlight> may result in device <highlight><bold>40</bold></highlight> being more comfortable or cosmetically acceptable to the patient. The use of device <highlight><bold>40</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 16</cross-reference> is substantially similar to the use of device <highlight><bold>50</bold></highlight>, and device <highlight><bold>40</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0060" lvl="0"><number>&lsqb;0060&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 17</cross-reference> illustrates an ophthalmic drug delivery device <highlight><bold>80</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>40</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 17</cross-reference>, device <highlight><bold>80</bold></highlight> has a geometry substantially similar to device <highlight><bold>40</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 16</cross-reference>, with the exception that a ramp <highlight><bold>45</bold></highlight> has been added to orbital surface <highlight><bold>12</bold></highlight> of body <highlight><bold>21</bold></highlight> proximate notch <highlight><bold>42</bold></highlight>. Ramp <highlight><bold>45</bold></highlight> is a slanted surface that preferably travels from scleral surface <highlight><bold>14</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Alternatively, ramp <highlight><bold>45</bold></highlight> may travel from a point within edge <highlight><bold>24</bold></highlight> of longitudinal part <highlight><bold>15</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Ramp <highlight><bold>45</bold></highlight> facilitates the accommodation of inferior oblique muscle <highlight><bold>107</bold></highlight> within notch <highlight><bold>42</bold></highlight> between transversal part <highlight><bold>18</bold></highlight> and stopper <highlight><bold>36</bold></highlight> when device <highlight><bold>80</bold></highlight> is implanted within eye <highlight><bold>90</bold></highlight>, as described hereinabove in connection with device <highlight><bold>50</bold></highlight>. Device <highlight><bold>80</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0061" lvl="0"><number>&lsqb;0061&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 18</cross-reference> schematically illustrates an ophthalmic drug delivery device <highlight><bold>65</bold></highlight> for the right human eye according a second preferred embodiment of the present invention. Device <highlight><bold>65</bold></highlight> may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required. Device <highlight><bold>65</bold></highlight> is particularly useful for localized delivery of active agents to the posterior segment of the eye. A preferred use for device <highlight><bold>65</bold></highlight> is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. </paragraph>
<paragraph id="P-0062" lvl="0"><number>&lsqb;0062&rsqb;</number> Device <highlight><bold>65</bold></highlight> generally includes a body <highlight><bold>29</bold></highlight> having a convex, dome-shaped, orbital surface <highlight><bold>12</bold></highlight> and a concave, dome-shaped, scleral surface <highlight><bold>14</bold></highlight> (not shown). Scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature that facilitates direct contact with sclera <highlight><bold>100</bold></highlight>. Most preferably, scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature equal to the radius of curvature <highlight><bold>91</bold></highlight> of an average human eye <highlight><bold>90</bold></highlight>. Orbital surface <highlight><bold>12</bold></highlight> is preferably designed with a radius of curvature that facilitates implantation under Tenon&apos;s capsule <highlight><bold>101</bold></highlight>. When viewed from the top, body <highlight><bold>21</bold></highlight> preferably has a generally &ldquo;C-shaped&rdquo; geometry with a longitudinal part <highlight><bold>17</bold></highlight>, a transversal part <highlight><bold>18</bold></highlight>, and a knee <highlight><bold>32</bold></highlight> therebetween. Longitudinal part <highlight><bold>17</bold></highlight> and transversal part <highlight><bold>18</bold></highlight> are preferably joined at knee <highlight><bold>32</bold></highlight> to form an angle of about ninety degrees. Longitudinal part <highlight><bold>17</bold></highlight> has a proximal end <highlight><bold>25</bold></highlight> and a rounded edge <highlight><bold>24</bold></highlight>. A stopper <highlight><bold>37</bold></highlight> forms the &ldquo;lower&rdquo; part of the C-shaped geometry and is preferably slightly elevated from the remainder of the generally convex orbital surface <highlight><bold>12</bold></highlight>. A notch <highlight><bold>42</bold></highlight> is located in longitudinal part <highlight><bold>17</bold></highlight> and is defined by transversal part <highlight><bold>18</bold></highlight> and stopper <highlight><bold>37</bold></highlight>. Similar to notch <highlight><bold>42</bold></highlight> of device <highlight><bold>50</bold></highlight> of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>, notch <highlight><bold>42</bold></highlight> of device <highlight><bold>65</bold></highlight> is designed to accommodate the origin of inferior oblique muscle <highlight><bold>107</bold></highlight>. Similar to stopper <highlight><bold>36</bold></highlight> of device <highlight><bold>50</bold></highlight>, stopper <highlight><bold>37</bold></highlight> is designed to prevent excessive advancement of device <highlight><bold>65</bold></highlight> toward optic nerve <highlight><bold>96</bold></highlight> through contact on the anterior border of inferior oblique muscle <highlight><bold>107</bold></highlight>. Transversal part <highlight><bold>18</bold></highlight> has a distal end <highlight><bold>58</bold></highlight>, a rounded edge <highlight><bold>28</bold></highlight>, and a well or cavity <highlight><bold>20</bold></highlight> having an opening <highlight><bold>64</bold></highlight> (not shown) to scleral surface <highlight><bold>14</bold></highlight> (not shown) for holding an inner core similar to those described above in connection with <cross-reference target="DRAWINGS">FIGS. 10 and 11</cross-reference>. Well <highlight><bold>20</bold></highlight> and opening <highlight><bold>64</bold></highlight> preferably have a generally oval shape. </paragraph>
<paragraph id="P-0063" lvl="0"><number>&lsqb;0063&rsqb;</number> The use of device <highlight><bold>65</bold></highlight> is substantially similar to the use of device <highlight><bold>50</bold></highlight> as described hereinabove. Device <highlight><bold>65</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0064" lvl="0"><number>&lsqb;0064&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 19</cross-reference> illustrates an ophthalmic drug delivery device <highlight><bold>67</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>65</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 19</cross-reference>, device <highlight><bold>67</bold></highlight> has a geometry substantially similar to device <highlight><bold>65</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 19</cross-reference>, with the exception that a ramp <highlight><bold>45</bold></highlight> has been added to orbital surface <highlight><bold>12</bold></highlight> of body <highlight><bold>29</bold></highlight> proximate notch <highlight><bold>42</bold></highlight>. Ramp <highlight><bold>45</bold></highlight> is a slanted surface that preferably travels from scleral surface <highlight><bold>14</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Alternatively, ramp <highlight><bold>45</bold></highlight> may travel from a point within edge <highlight><bold>24</bold></highlight> of longitudinal part <highlight><bold>17</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Ramp <highlight><bold>45</bold></highlight> facilitates the accommodation of inferior oblique muscle <highlight><bold>107</bold></highlight> within notch <highlight><bold>42</bold></highlight> between transversal part <highlight><bold>18</bold></highlight> and stopper <highlight><bold>37</bold></highlight> when device <highlight><bold>67</bold></highlight> is implanted within eye <highlight><bold>90</bold></highlight>, as described hereinabove in connection with device <highlight><bold>50</bold></highlight>. Device <highlight><bold>67</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0065" lvl="0"><number>&lsqb;0065&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 20</cross-reference> schematically illustrates an ophthalmic drug delivery device <highlight><bold>52</bold></highlight> for the right human eye according a third preferred embodiment of the present invention. Device <highlight><bold>52</bold></highlight> may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required. Device <highlight><bold>52</bold></highlight> is particularly useful for localized delivery of active agents to the posterior segment of the eye. A preferred use for device <highlight><bold>52</bold></highlight> is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. </paragraph>
<paragraph id="P-0066" lvl="0"><number>&lsqb;0066&rsqb;</number> Device <highlight><bold>52</bold></highlight> generally includes a body <highlight><bold>39</bold></highlight> having a convex, dome-shaped, orbital surface <highlight><bold>12</bold></highlight> and a concave, dome-shaped scleral surface <highlight><bold>14</bold></highlight> (not shown). Scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature that facilitates direct contact with sclera <highlight><bold>100</bold></highlight>. Most preferably, scleral surface <highlight><bold>14</bold></highlight> is designed with a radius of curvature equal to the radius of curvature <highlight><bold>91</bold></highlight> of an average human eye <highlight><bold>90</bold></highlight>. Orbital surface <highlight><bold>12</bold></highlight> is preferably designed with a radius of curvature that facilitates implantation under Tenon&apos;s capsule <highlight><bold>101</bold></highlight>. When viewed from the top, body <highlight><bold>39</bold></highlight> preferably has a generally &ldquo;L-shaped&rdquo; geometry with a longitudinal part <highlight><bold>15</bold></highlight>, a transversal part <highlight><bold>18</bold></highlight>, and a knee <highlight><bold>32</bold></highlight> therebetween. Longitudinal part <highlight><bold>15</bold></highlight> and transversal part <highlight><bold>18</bold></highlight> are preferably joined at knee <highlight><bold>32</bold></highlight> to form an angle of about ninety degrees. Similar to notch <highlight><bold>42</bold></highlight> of device <highlight><bold>50</bold></highlight> of <cross-reference target="DRAWINGS">FIGS. 7 and 9</cross-reference>, longitudinal part <highlight><bold>15</bold></highlight> and transversal part <highlight><bold>18</bold></highlight> of device <highlight><bold>52</bold></highlight> form a region <highlight><bold>43</bold></highlight> designed to accommodate the origin of inferior oblique muscle <highlight><bold>107</bold></highlight>. Longitudinal part <highlight><bold>15</bold></highlight> has a proximal end <highlight><bold>25</bold></highlight> and a rounded edge <highlight><bold>24</bold></highlight>. Transversal part <highlight><bold>18</bold></highlight> has a distal end <highlight><bold>58</bold></highlight>, a rounded edge <highlight><bold>28</bold></highlight>, and a well or cavity <highlight><bold>20</bold></highlight> having an opening <highlight><bold>64</bold></highlight> (not shown) to scleral surface <highlight><bold>14</bold></highlight> for holding an inner core similar to those described above in connection with <cross-reference target="DRAWINGS">FIGS. 10 and 11</cross-reference>. Well <highlight><bold>20</bold></highlight> and opening <highlight><bold>64</bold></highlight> preferably have a generally oval shape. </paragraph>
<paragraph id="P-0067" lvl="0"><number>&lsqb;0067&rsqb;</number> The use of device <highlight><bold>52</bold></highlight> is substantially similar is substantially similar to the use of device <highlight><bold>50</bold></highlight> as described hereinabove. Device <highlight><bold>52</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0068" lvl="0"><number>&lsqb;0068&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 21</cross-reference> illustrates an ophthalmic drug delivery device <highlight><bold>54</bold></highlight>, a slight modification of ophthalmic drug delivery device <highlight><bold>52</bold></highlight> that is useful for certain implantations of the present invention. As shown in <cross-reference target="DRAWINGS">FIG. 21</cross-reference>, device <highlight><bold>54</bold></highlight> has a geometry substantially similar to device <highlight><bold>52</bold></highlight> of <cross-reference target="DRAWINGS">FIG. 20</cross-reference>, with the exception that a ramp <highlight><bold>45</bold></highlight> has been added to orbital surface <highlight><bold>12</bold></highlight> of body <highlight><bold>29</bold></highlight> proximate region <highlight><bold>43</bold></highlight>. Ramp <highlight><bold>45</bold></highlight> is a slanted surface that preferably travels from scleral surface <highlight><bold>14</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Alternatively, ramp <highlight><bold>45</bold></highlight> may travel from a point within edge <highlight><bold>24</bold></highlight> of longitudinal part <highlight><bold>15</bold></highlight>, on a first end, to orbital surface <highlight><bold>12</bold></highlight> on a second end. Ramp <highlight><bold>45</bold></highlight> facilitates the accommodation of inferior oblique muscle <highlight><bold>107</bold></highlight> within region <highlight><bold>43</bold></highlight> when device <highlight><bold>54</bold></highlight> is implanted within eye <highlight><bold>90</bold></highlight>, as described hereinabove in connection with device <highlight><bold>50</bold></highlight>. Device <highlight><bold>54</bold></highlight> may be made using techniques substantially similar to device <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0069" lvl="0"><number>&lsqb;0069&rsqb;</number> From the above, it may be appreciated that the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a variety of pharmaceutically active agents to the eye, and particularly to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies. The surgical procedure for implanting such devices is safe, simple, quick, and capable of being performed in an outpatient setting. Such devices are easy and economical to manufacture. Furthermore, because of their capability to deliver a wide variety of pharmaceutically active agents, such devices are useful in clinical studies to deliver various ophthalmic agents that create a specific physical condition in a patient. </paragraph>
<paragraph id="P-0070" lvl="0"><number>&lsqb;0070&rsqb;</number> The present invention is illustrated herein by example, and various modifications may be made by a person of ordinary skill in the art. For example, although the present invention is described hereinabove with reference to an ophthalmic drug delivery device having a generally &ldquo;F-shaped&rdquo;, &ldquo;C-shaped&rdquo;, or &ldquo;L-shaped&rdquo; geometry when viewed from the top, other geometries may be used, especially if they facilitate the placement of the device under the inferior oblique muscle and the location of pharmaceutically active agent over the macula when the device is implanted on the outer surface of the sclera and below the Tenon&apos;s capsule of the human eye. </paragraph>
<paragraph id="P-0071" lvl="0"><number>&lsqb;0071&rsqb;</number> It is believed that the operation and construction of the present invention will be apparent from the foregoing description. While the apparatus and methods shown or described above have been characterized as being preferred, various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined in the following claims. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<heading lvl="1">What is claimed is: </heading>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. A drug delivery device for a human eye, said eye having a sclera, an inferior oblique muscle, and a macula, said device comprising: 
<claim-text>a pharmaceutically active agent; and </claim-text>
<claim-text>a geometry that facilitates an implantation of said device on an outer surface of said sclera, beneath said inferior oblique muscle, and with said pharmaceutically active agent disposed above said macula.</claim-text>
</claim-text>
</claim>
</subdoc-claims>
<subdoc-drawings id="DRAWINGS">
<heading lvl="0" align="CENTER">Drawings</heading>
<representative-figure>NONE</representative-figure>
<figure id="figure-D00001">
<image id="EMI-D00001" file="US20030003129A1-20030102-D00001.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00002">
<image id="EMI-D00002" file="US20030003129A1-20030102-D00002.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00003">
<image id="EMI-D00003" file="US20030003129A1-20030102-D00003.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00004">
<image id="EMI-D00004" file="US20030003129A1-20030102-D00004.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00005">
<image id="EMI-D00005" file="US20030003129A1-20030102-D00005.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00006">
<image id="EMI-D00006" file="US20030003129A1-20030102-D00006.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00007">
<image id="EMI-D00007" file="US20030003129A1-20030102-D00007.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00008">
<image id="EMI-D00008" file="US20030003129A1-20030102-D00008.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00009">
<image id="EMI-D00009" file="US20030003129A1-20030102-D00009.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00010">
<image id="EMI-D00010" file="US20030003129A1-20030102-D00010.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00011">
<image id="EMI-D00011" file="US20030003129A1-20030102-D00011.TIF" imf="TIFF" ti="DR"/>
</figure>
<figure id="figure-D00012">
<image id="EMI-D00012" file="US20030003129A1-20030102-D00012.TIF" imf="TIFF" ti="DR"/>
</figure>
</subdoc-drawings>
</patent-application-publication>
